World Regenerative Medicine Market

World Regenerative Medicine Market

This report analyzes the worldwide markets for Regenerative Medicine in Millions of US$. The report provides separate comprehensive analytics for the US, Japan, and Europe. Annual forecasts are provided for each region for the period of 2003 through 2015. The report profiles 106 companies including many key and niche players worldwide such as BioVest International, Inc., Curis, Inc., Cytori Therapeutics, Inc., DeveloGen AG, Forticell Bioscience, Inc., Geron Corporation, Human Genome Sciences, Inc., IsoTis, Inc., Kiadis Pharma B.V., LifeCell Corporation, Osiris Therapeutics, Inc., Tepha Inc., and TiGenix N.V. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

REGENERATIVE MEDICINE MCP-1241
A GLOBAL STRATEGIC BUSINESS REPORT


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. Industry Overview II-1
Regenerative Medicine - the Past, the Present, & the Future II-1
Another Revolution in the Making? II-2
Conventional Chemical Medicine Vs Regenerative Medicine II-2
The Need for Regenerative Medicine II-3
Regenerative Medicine Throws in Several New Therapies II-3
What’s in Store? II-3
Regenerative Medicine to Arrest Ageing II-3
Thriving on an Aging World Population II-4
Faster Healing Process II-4
Regenerative Medicine to Overcome Donor Organs Shortage II-4
Possible Scenarios II-5
Stem Cell Research - Not Just Another Medical Advancement II-5
Key Issues At Play II-6
Market Potential II-6
Regenerative Medicine in Bone and Joint Applications II-6
US Corners a Lion’s Share II-6
Growth Drivers II-6
Trends & Issues II-7
Biomaterials Sought After in Regenerative Medicine II-7
Upbeat Market for Cell-based Tissue Engineering II-7
Progenitor Cell Therapy to Witness No Holds Barred Growth II-8
Players Embrace Automation in Production Facilities II-8
Contract Manufacturing, a Growing Sector II-9
Investors Wary of Funding Regenerative Medicine II-9
Regenerative Medicine Field Lags Behind due to Segregated Focus II-9
Challenges to Be Encountered by Tissue Engineering Companies II-10
Activity in the Field of Regenerative Medicine II-10

2. Product Overview II-12
Regenerative Medicine Advances in Four Phases II-12
Human Substances II-12
Tissue Engineering II-12
Therapeutic Cloning II-12
Nanotechnology-Driven Biomaterials II-12
Types of Regenerative Medicine II-12
Type I - Regenerative Medicine II-13
Human Proteins and Genes are Drugs in Regenerative Medicine II-13
Type-2 Regenerative Medicine II-13
Therapies Based on Human Cells and Tissues II-13
Type-3 Regenerative Medicine II-15
Based on Embryonic Stem Cells II-15
The Opponents of the ESC Theory II-16
Embryonic Stem Cells - Shortcomings II-16
Type-4 Regenerative Medicine II-17
Based on Novel Materials / Material Science Advancements II-17
Overview of Major Regenerative Medicine Techniques II-18
Natural Regenerative Proteins II-18
Tissue Engineering Capable of Culturing Replacement Organs II-18
All About Stem Cells II-19
Adult Stem Cells II-19
Adult Stem Cell Research Eludes Ethical Dispute II-19
hESC - Highly Capable of Differentiating and Multiplying II-19
Stem Cell Research in Development of Regenerative Medicine II-20
Neural Stem Cell to Restore Memory Functioning II-20
Pancreatic Islet Cells to Control Blood Sugar in Diabetics II-20
Therapeutic Cloning to Cure Parkinson’s II-21

3. Regulatory Environment II-22
Regulatory Norms Governing ES Cell Research II-22
Milestones in the Human Embryonic Stem Cell Research: 2001 II-22
Legality of ES Cell Use in Major Developed Nations II-22

4. Technological Innovations / Breakthroughs II-23
Celprogen Launches 11 Cancer Stem Cells II-23
Biovest International Launches AutovaxID™ II-23
Stelic Institute Announces New Treatment Method for Acute
Liver Failure II-23
TissueGene Initiates Phase 1 Clinical Trials for TG-C II-24
ISTO Announces FDA’s IND Approval for Neocartilage Graft II-24
Cook Biotech Introduces Surgisis® AFP™ Anal Fistula Plug II-24
Korean Scientists Make a Major Breakthrough in Stem Cell Lines II-24
Japanese Researchers Regenerate Jaw Bone II-25
Geron Researchers Differentiate Hepatocytes from hESCs II-25
Geron Demonstrates Potential of hESCs in Treatment of
Parkinson’s disease II-25
Geron Researches Cardiomyocytes for Heart Disease II-26
Endovasc Announces New Findings at Texas Heart Institute Research II-26
Geron and Celera Genomics Complete Characterization of Active
Genes in hESCs II-26
Rockefeller University Develops Solution for Maintaining
Plupotency in hESCs II-27

5. Recent Industry Activity II-28
Cytori and Green Hospital Supply Ink Strategic Equity Deal II-28
RNL Bio Establishes Research Unit at Newcastle University II-28
Tengion Begins Third Phase II Clinical Trial of Neo-Bladder
Augment™ II-28
Organogenesis Signs MoU with NTEC II-28
BioTime Establishes New Stem Cell Division II-29
Integra Life Sciences Acquires IsoTis, Inc. II-29
NovaThera and Gamida Join Hands for Developing Cell
Therapeutics for Lung Regeneration II-29
Tigenix Teams Up With Fidea to Develop Biological Joint Implants II-30
Scotland Plans to Build Center for Regenerative Medicine in
Edinburgh II-30
Celmed BioSciences Merges with Kiadis II-31
Bayer Acquires Schering AG II-31
Genentech Files IND Application with FDA II-31
National Stem Cell Holding and Azurel Merge II-31
StemCells and Stem Cell Therapeutics in Licensing Agreement II-31
co.don Signs Distribution Agreement with Austrian Company II-32
Olympus to Increase Investment in Olympus-Cytori, Inc. II-32
Geron and University of Edinburgh in Collaboration for
Development of hESCs II-32
Ortho-McNeil Acquires ColBar LifeScience II-32
CCMB to Establish Research Center for Regenerative Medicine II-33
Cambrex and Cytori Therapeutics in Strategic Alliance II-33
co.don Signs Distribution Agreement with XMEDICA II-33
NCRM Signs MoU with Eye Hospital for Occular Research II-33
Theregen Receives Funding from Sanderling Ventures II-34
Musculoskeletal Transplant Foundation Signs Research and
Investment Agreements with ProChon Biotech II-34
Olympus and Cytori Therapeutics Establish Olympus-Cytori, Inc. II-34
StemCo Biomedical is now Aldagen, Inc. II-35
Healtheuniverse Establishes R&D Base in Singapore II-35
BioMimetic Receives FDA Approval for GEM 21S® II-35
Gambro and Nephrogen in Research Partnership II-36
UC-Berkley Bags US$ 2.5 Million Grant from CIRM II-36
MacroPore Biosurgery Receives US$ 11 Million through Equity
Placement II-36
World’s third Largest Laboratory for Regenerative Medicine II-37
Ortec Forms a Joint Venture with HAPTO II-37
Curis Extends Agreement with Genentech II-37
Curis Strikes a Deal with Genentech II-37
Curis Collaborates with Wyeth Pharmaceuticals II-37
co.don Strikes a Deal with Bioengi Ltd II-37
StemCells Licenses Stem Cell Technology to ReNeuron II-37
Osiris Receives FDA Approval to Commence Stem Cell Trial for
Knee Repair II-38
Geron Corporation and BRC Establish TA Therapeutics Limited II-38
Celmed BioSciences Pockets NewBiotics II-38
Celmed BioSciences Collaborates with Gambro BCT II-38
Ortec Collaborates with ESI II-38
BMPI in Alliance with Luitpold Pharmaceuticals II-39
BioVest International Enters into a Supply Agreement with
Bioventix II-39
Geron Inks Two Licensing Agreements with Revivicor II-39
Geron Enters into a Licensing Agreement with P&G II-39
Roslin Institute, Geron, CXR Strike a Deal II-39
Geron Signs a Licensing Agreement with Xcellsyz II-40
Geron Inks a Pact with Merix II-40
Agreement between HGSI and GlaxoSmithKline II-40
MacroPore Biosurgery Sells off Bioresorbable Thin Film Product
Line II-40
Jenapharm Divests Therapeutics Business II-40
Celmed BioSciences Divests Celmed USA II-41
Schering Extends Research Facility in Japan II-41
Stem Cell Research Gets Approval in California II-41
Accentia Acquires Majority Stake in BioVest II-41
DeveloGen Merges with Peptor II-41
DeveloGen Partners with Evotec OAI II-41
LifeCell Collaborates with NSCC II-42
LifeCell Corporation Accords with SHO II-42
Osiris Enters into a Licensing Agreement with JCR II-42
TiGenix Inks a Pact with IQL II-42
BioVest International Signs an Agreement with BioE, Inc II-42
PPL Therapeutics Divests Regenerative Medicine Business II-43
Osiris Bags EU Patent for Matter Composition in Adult, Human MSC II-43
J-TEC and Nagoya University Develop Cell Culture System II-43
Marubeni Takes a Minor Stake in GBS II-43
Tepha Develops New Biomaterials for Regenerative Medicine II-43
Gunze Inaugurates Regenerative Medicine Research Facility II-44
Geron Corporation and Exeter Life Sciences Establish stART
Licensing, Inc II-44
Cambrex Establishes New Facility to Manufacture Cell Therapy II-44

6. Focus on Select Global Players II-45
BioVest International, Inc. (US) II-45
Curis, Inc. (US) II-45
Cytori Therapeutics, Inc. (US) II-46
DeveloGen AG (Germany) II-46
Forticell Bioscience, Inc. (US) II-47
Geron Corporation (US) II-47
Human Genome Sciences, Inc. (US) II-48
IsoTis, Inc. (US) II-48
Kiadis Pharma B.V. II-48
LifeCell Corporation (US) II-49
Osiris Therapeutics, Inc. (US) II-49
Tepha Inc. (US) II-50
TiGenix N.V. (Belgium) II-50

7. Global Market Perspective II-52
Table 1: World Recent Past, Current & Future Market Analysis
for Regenerative Medicine Products for Bone and Joint
Applications by Geographic Region - US, Japan and Europe
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2010 (includes corresponding
Graph/Chart) II-52

Table 2: World Long-term Projections for Regenerative Medicine
Products for Bone and Joint Applications by Geographic Region
- US, Japan and Europe Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) II-52

Table 3: World 8-Year Perspective for Regenerative Medicine
Products for Bone and Joint Applications by Geographic Region
- Percentage Breakdown of Dollar Sales for US, Japan and
Europe for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) II-53

III. MARKET

1. The United States III-1
A.Market Analysis III-1
Market Potential III-1
Regenerative Medicine in Bone and Joint Applications III-1
Regenerative Therapy - Best Fit for Joint Problems III-1
Millions of American Patients Put their Hope in Stem Cell
Research III-2
Table 4: Prevalence of Various Diseases in the US III-2
US Witnesses Mixed Response for Government Support for hESC
Research III-3
CBI’s Human Tissue Products for Treating Liver Failure and
Diabetes III-3
Market for Liver and Pancreas Transplantation III-4
Implantable Regenerative Products Take Over Sports Medicine III-4
Key Players III-4
BioVest International, Inc. III-4
Curis, Inc. III-5
Cytori Therapeutics, Inc. III-5
Geron Corporation III-6
Human Genome Sciences, Inc. III-6
IsoTis, Inc. III-7
Osiris Therapeutics, Inc. III-7
Revivicor, Inc.. III-7
Tepha Inc. III-8
Other Key Players & Activities III-8
Technological Developments III-10
Strategic Developments III-13
B.Market Analytics III-23
Table 5: US Recent Past, Current & Future Analysis for
Regenerative Medicine Products for Bone and Joint
Applications - Annual Sales Figures in US$ Million for Years
2003 through 2010 (includes corresponding Graph/Chart) III-23

Table 6: US Long-Term projections for Regenerative Medicine
Products for Bone and Joint Applications - Annual Sales
Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-23

2. Japan III-24
A.Market Analysis III-24
Market Potential III-24
Research Activity in Regenerative Medicine Field III-24
More Companies Eye the Regenerative Medicine Potential III-24
Competition Heats up Behind Closed Doors III-25
Japanese Firms Need to Catch Up with US and European
Competitors III-25
Science Ministry Rolls Out Regenerative Medicine Project III-25
Regenerative Medicine Exempted from Ban on Human Cloning III-26
Technological Developments III-26
Strategic Developments III-27
Developments in Recent Past III-27
B.Market Analytics III-28
Table 7: Japanese Recent Past, Current & Future Analysis for
Regenerative Medicine Products for Bone and Joint
Applications - Annual Sales Figures in US$ Million for Years
2003 through 2010 (includes corresponding Graph/Chart) III-28

Table 8: Japanese Long-Term projections for Regenerative
Medicine Products for Bone and Joint Applications - Annual
Sales Figures in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) III-29

3. Europe III-30
A.Market Analysis III-30
Germany III-30
Key Players III-30
co.don AG III-30
DeveloGen AG III-30
United Kingdom III-31
Belgium III-31
Select Player. III-31
TiGenix N.V. III-31
Strategic Developments III-32
B.Market Analytics III-36
Table 9: European Recent Past, Current & Future Analysis for
Regenerative Medicine Products for Bone and Joint
Applications - Annual Sales Figures in US$ Million for Years
2003 through 2010 (includes corresponding Graph/Chart) III-36

Table 10: European Long-Term projections for Regenerative
Medicine Products for Bone and Joint Applications - Annual
Sales Figures in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) III-36

4. Review of Regenerative Medicine in Other Geographic Markets III-37

4a. Canada III-37
University of Toronto - Spearheading Regenerative Medicine
Research III-37
Strategic Developments III-37

4b. Asia-Pacific III-39
China III-39
Substantial Government Support III-39
India III-39
CSIR- Leading the way in Regenerative Medicine Research III-39
High Growth Opportunities III-39
Australia III-40
Key Player III-40
Stem Cell Sciences III-40
South Korea III-40
Malaysia III-40
Singapore III-41
Strategic Developments III-41

4c. Rest of World III-44
Argentina III-44
Israel III-44
Select Major Players III-44
Colbar R&D Ltd. III-44
ProChon Biotech Ltd.. III-44
South Africa III-45
Strategic Development III-45

IV. COMPETITIVE LANDSCAPE